Reaction
Retinal Vasculitis reporting signals
As of the last recalculation, Retinal Vasculitis appears in 1,171 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is FARICIMAB (PRR 141.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Faricimab | 61 | 141.1 | 142.2 |
| Aflibercept | 107 | 67.0 | 67.2 |
| Vancomycin | 160 | 56.8 | 57.0 |
| Vancomycin Hydrochloride | 171 | 53.8 | 54.0 |
| Ranibizumab | 59 | 41.5 | 41.6 |
| Prednisolone Acetate | 18 | 31.4 | 31.4 |
| Nevirapine | 13 | 25.9 | 25.9 |
| Ganciclovir | 13 | 22.8 | 22.8 |
| Ganciclovir Sodium | 13 | 22.1 | 22.1 |
| Moxifloxacin | 14 | 17.9 | 17.9 |
| Moxifloxacin Hydrochloride | 19 | 16.9 | 16.9 |
| Lidicaine | 44 | 16.6 | 16.6 |
| Burn Relief | 44 | 16.6 | 16.6 |
| Lidocaine Hydrochloride And Epinephrine | 44 | 16.5 | 16.6 |
| Lidocaine, Menthol | 44 | 16.3 | 16.4 |
| Dorzolamide Hydrochloride And Timolol Maleate | 7 | 15.8 | 15.8 |
| Lidocaine Hydrochloride And Epinephrine Bitartrate | 45 | 15.5 | 15.6 |
| Lidocaine 4% | 44 | 14.9 | 14.9 |
| Lidocaine | 44 | 13.9 | 13.9 |
| Triamcinolone Acetonide | 19 | 11.1 | 11.1 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 14 | 10.7 | 10.8 |
| Brinzolamide | 5 | 10.3 | 10.3 |